ArticleMedical principles and practice : international journal of the Kuwait University, Health Science Centre2026
Clinical Outcomes of Low-Dose Intranasal Midazolam for Severe Gag Reflex in Endodontic Patients: A Retrospective Case Series Study.
Article in Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe severe gag reflex (SGR) is an involuntary protective response to foreign substances. SGR presents a significant obstacle to the provision of standard dental care. This retrospective case series study evaluates the clinical outcomes and the feasibility of low-dose (2.5 mg) intranasal midazolam administration on SGR control in uncooperative patients with Gagging Severity Index 5. MATERIAL AND
methodsThis retrospective study includes patients who could not receive endodontic treatment due to the SGR and were referred for general anesthesia. Data from 13 adult patients, one of whom had an intellectual disability, were used. A fixed low-dose (2.5 mg) of intranasal midazolam was administered under the control of an anesthesiologist. Clinical monitoring (vital signs) focused on respiratory effort, skin color, and the maintenance of verbal commands. Endodontic treatment was started with local anesthesia approximately 10 min after 2.5 mg midazolam administration, averaging 40 min per session.
resultsAll patients remained conscious, responsive to verbal commands, and cooperative during treatment. One patient received intranasal saline as an ad hoc clinical observation, but midazolam was later administered due to persistent gagging. SGR was effectively managed in all patients during initial and ongoing sessions of endodontic treatment without side effects. All necessary dental procedures, including root canal treatment and restorations, were performed comfortably.
conclusionA conservative 2.5 mg dose of intranasal midazolam can safely control SGR in adult patients during long and complex dental procedures, such as endodontic treatment. Also, it is a practical, less invasive alternative to general anesthesia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.